Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Public ClinicalTrials.gov record NCT01823198. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
NK Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase I/II trial studies the side effects and best dose of donor natural killer cells when given together with donor stem cell transplant and to see how well they work in treating patients with myeloid malignancies that are likely to come back or spread. Giving chemotherapy, such as busulfan and fludarabine phosphate, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural killer cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Study identification
- NCT ID
- NCT01823198
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 63 participants
Conditions and interventions
Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Acute Erythroid Leukemia
- Acute Megakaryoblastic Leukemia
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Acute Myeloid Leukemia in Remission
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Blasts Under 20 Percent of Bone Marrow Nucleated Cells
- Blasts Under 20 Percent of Peripheral Blood White Cells
- Chronic Myelomonocytic Leukemia
- High Risk Myelodysplastic Syndrome
- Myelodysplastic Syndrome
- Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Therapy-Related Acute Myeloid Leukemia
- Therapy-Related Myelodysplastic Syndrome
Interventions
- Aldesleukin Biological
- Allogeneic CD56-positive CD3-negative Natural Killer Cells Biological
- Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Busulfan Drug
- Fludarabine Phosphate Drug
- Laboratory Biomarker Analysis Other
- Peripheral Blood Stem Cell Transplantation Procedure
- Pharmacological Study Other
Biological · Procedure · Drug + 1 more
Eligibility (public fields only)
- Age range
- 7 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 10, 2013
- Primary completion
- May 9, 2022
- Completion
- May 9, 2022
- Last update posted
- Nov 6, 2023
2013 – 2022
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01823198, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 6, 2023 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01823198 live on ClinicalTrials.gov.